Background: GI147211, a 10,11-ethylenedioxy substituted analogue of camptothecin (CPT), was brought into clinical development because of its higher water solubility and greater potency as compared to topotecan (TPT). The antitumor activity of GI147211 as second-line therapy in small-cell lung cancer (SCLC) was assessed after stratification of patients in refractory (no response to initial treatment or relapse within three months from last cycle) and chemosensitive (relapse more than three months from last cycle).
Introduction GI147211 (7-[4-methylpiperazinomethylene]-10,ll-ethylenedioxy-20(s)-camptothecin dihydrochloride) is a watersoluble analogue of the DNA topoisomerase I inhibitor camptothecin (CPT). Analogous to other 10,11-ethylene or methylene-dioxy substituted CPT analogues, GI147211 was shown to be two-to three-fold more potent than topotecan (TPT) at inhibiting topo I, three-to five-fold more cytotoxic than TPT in a series of human tumor cell lines and to have antitumor activity against several human tumor xenografts comparable to that of TPT [1] . The antitumor activity appeared to be schedule-dependent and was higher with more frequent or prolonged administrations. The most promising results, with complete tumor regressions of established human tumor xenografts, were achieved in the HT-29 colon and MX-1 mammary carcinoma models [2] .
In mice, rats and dogs the pharmacokinetics of GI147211 was linear with a high volume of distribution, low renal clearance and with the two main metabolic species, the lactone and the carboxylate, in equilibrium in plasma [3] . In acute toxicity studies in mice and rats and in subchronic toxicity studies in rats and dogs target organs of toxicity were bone marrow and GI tract.
The toxicology profile was confirmed in phase I studies for which repeated or prolonged schedules of administration were selected.
In the d x 5 study [4] both neutropenia and thrombocytopenia were dose-limiting in patients with extensive prior treatment, as defined by wide field radiation, mitomycin C, carboplatin or nitrosoureas-containing regimens, four cycles of cyclophosphamide, adriamycin or methotrexate; for this group of patients the maximum tolerable dose (MTD) was fixed at 1.5 mg/m 2 /day and the dose recommended for phase II evaluation was 1.2 mg/m 2 /day. Plasma pharmacokinetics, described by a three-compartment model, appeared to be linear within 0.6 mg/m 2 /day and 1.75 mg/m 2 /day; renal excretion accounted for 11% of dose. Small-cell lung cancer (SCLC) was selected for phase II evaluation because of the significant activity reported with TPT mainly in patients with sensitive tumors [5] and of the need for finding new active agents with a favorable toxicity profile in this neoplasm. A design similar to the one implemented in the phase II study of TPT, with separate evaluation of sensitive and refractory patients, was applied, since in SCLC, as in other tumor types, the antitumor activity of second-line therapy was shown to be dependent upon response to initial chemotherapy and duration of response [6] .
The objectives of the present study were to assess the antitumor activity of GI 147211 as salvage treatment in patients with both refractory and sensitive advanced SCLC, to further characterize its toxic effects and the presence of a pharmacokinetic-pharmacodynamic relationship. The pharmacokinetic and pharmacodynamic results were the subject of a separate paper [7] .
From a 100 ml dosing solution using Dextrose 5W provided by Glaxo the volume to be replaced by the volume of GI147211 was removed and the correct dose of GI147211 was added. GI147211 was given at the dose of 1.2 mg/m 2 /day as a 30-min infusion for five consecutive days, repeated every three weeks or upon recovery (WBC ^1.5 x 10 9 /l, platelets ^ 100 x 10 9 /l) up to a maximum delay of two weeks The dose was decreased to 0.9 mg/m 2 /day in instances of grade 4 absolute neutrophil count nadir (ANC) or platelet nadir; the dose could be increased to 1.5 mg/m 2 /day in instances of no hematologic or nonhematologic toxicity in the previous cycle. Tumor response was evaluated after two cycles, patients showing progressive disease (PD) went off study, those with disease stabilization (NC) could receive further cycles at the discretion of the investigator, while responders continued treatment until PD or excessive toxicity.
Response and toxicity criteria
Follow-up studies included weekly complete blood counts and, every three weeks, full biochemistry, urine and guaiac stool test. Guaiac stool test was performed also on day 5 of each cycle. Standard WHO response criteria were used [8] ; toxicities were graded according to the NCI Common Toxicity Criteria for cancer clinical trials.
Study design and statistical considerations
Patients were stratified as refractory (patients who responded to initial chemotherapy but relapsed in the three succeeding months or who, while on primary chemotherapy, showed PD after at least one cycle or NC after at least two cycles) or potentially sensitive (patients who responded to initial chemotherapy and relapsed more than three months after the end of chemotherapy). The initial study design planned for a sample size of 40 patients per stratification arm with a 95% confidence interval (95% CI) for a true response rate of 17%. Subsequently, after 18 months from starting, because of the lower than expected accrual and of the possibility of verifying the true antitumor activity of GI 147211 by treating less patients over a more reasonable period of time, a more practical Gehan design was implemented with only 25 evaluable patients in case of $ 4 responders in the first 14 patients [9] . Background and safety analyses were done in all patients who received at least one dose of GI147211, while the efficacy analysis was performed in those patients who received the drug without deviating significantly from the protocol.
Results

Patients and methods
Eligibility
To be eligible for the study patients had to have: histologically or cytologically confirmed progressive recurrent SCLC after first-line chemotherapy, at least one bidimensionally measurable lesion, World Health Organization (WHO) performance status ^2 . one prior chemotherapy regimen that did not include CPT analogues, adequate hematologic (WBC 3=3.0 x 10 9 /l, platelet count 3= 100 x 10 9 /l), liver (bilirubin <26 umol/1, ALT and AST ^2 x the upper limit of normal unless related to liver metastasis) and renal (creatinine 4 140 umol/1) functions, no signs of brain or leptomeningeal disease, no history of congestive cardiac failure, no active heart disease requiring anti-arrhythmics, and to have given their written informed consent. 
Patient characteristics
From March 1995 to August 1997 a total of 67 patients were entered from 16 European centers (Table 1) . Of 38 patients in the chemosensitive arm, 1 did not begin the treatment and 1 was ineligible because of cardiac arrhythmia. Of 29 refractory patients, 1 was ineligible because of a lack of confirmation of progressive recurrence. Of 66 treated patients, 2 additional patients in the chemosensitive group were not evaluable because of early death after the first cycle in one instance and evaluation done only by Echo in the other, thus leaving a total of 62 evaluable patients (28 in the refractory and 34 in the chemosensitive group).
The majority of patients in both groups had a WHO PS of 1; all had been pretreated with chemotherapy; 6 patients in the refractory and 23 in the chemosensitive group had also received prior irradiation. The median time between the last chemotherapy and the first infusion of GI147211 was 2.1 months (0.2-7.5 months) in the refractory and 7.9 months (from 3.2-19.6) in the chemosensitive group. Of 66 treated patients, 17 (26%) and 13 (20%) received 2 and 3 cycles, respectively. The dose was decreased in 16 patients (24%) and increased in 5 (7.5%).
Response to treatment
Of 66 treated patients, 11 (16.6%) achieved a PR (3 in the refractory and 8 in the chemosensitive group) with a response rate of 10.3 (95% CI: 2.2%-27%) and 21.1% (95% CI: 9.5%-37%) in the two arms. In addition, 21 patients (32%) had NC. The median duration of PR was 160 days (129-189 days) in the refractory and 146.5 (77-321 days) in the chemosensitive group. All refractory patients had been pretreated with etoposide and 5 had a time interval between 6 and 7.5 months from the last cycle of chemotherapy to the start of GI147211. One of the three refractory patients who achieved a PR had a time interval of six months while the remaining two had a time interval of two and three months, respectively; all but one of the eight partial responders in the chemosensitive group had received prior treatment with podophyllotoxins and platinum compounds ( Table 2) .
Toxicity
Hematological toxicity was common, consisting mainly of grade 1-2 anemia (91% of courses), neutropenia (grades 3-4 in 25% of courses) and thrombocytopenia (grades 3-4 in 23% of courses) ( Table 3 ). The incidence and degree of hematological toxicity were comparable in refractory and chemosensitive patients. Infections occurred in 7% of cycles. One patient, a 67-year-old woman, pretreated with four courses of combination chemotherapy and radiotherapy, suffered from a drug- related septic shock after the first cycle and died nine days later of tumor progression. Non-hematological toxicity, which was comparable in the two groups of patients, consisted mainly of grades 1-2 malaise (34% of cycles), nausea (22% of cycles), vomiting (11% of cycles), and alopecia. Grade 3 stomatitis and diarrhea and occurred in one and two patients, respectively.
Discussion
The topo I inhibitor GI147211 was brought into clinical development because of its greater water solubility and higher potency at inhibiting the target enzyme as compared to the leading compound Topotecan (TPT), which is considered one of the most active agents in SCLC.
The evaluation of the antitumor activity of GI147211 in SCLC as second-line therapy was one of the most crucial and interesting steps in its clinical development. To assess the advantages of treatment with GI147211 over that with TPT, a study design similar to the one followed for TPT, with a prospective stratification of patients between refractory and chemosensitive accord-ing to response to prior chemotherapy and duration of response, was implemented [5] . Similar eligibility criteria were followed as well as criteria for response and toxicity.
With GI147211 the overall response rate (16.6%; 95% CI: 8.5%-27.5%) was lower than with TPT (37.8%; 95% CI: 23.8%-53.5%); only PRs were observed with GI147211, while CR were also reported with TPT. The median response duration with GI147211 was shorter (4.8 months) than with TPT (7.6 months). From the standpoint of activity these results indicate that GI147211 is active in pretreated SCLC; this finding is supported by the 10.3% response rate (95% CI: 2.2%-27%) achieved in refractory patients. With TPT, a response rate of 6.4% (95% CI: 1.3%-17.5%) has been reported in refractory patients, while a very promising response rate has been achieved in patients sensitive to first-line chemotherapy. Even though the two topo I inhibitors were not directly compared, we could conclude that GI147211, at the dose and schedule tested in the present study, has an antitumor activity almost comparable to that of TPT in pretreated SCLC. In view of the already advanced clinical development of TPTwe could also conclude that further clinical development of GI147211 was not worthwhile.
Toxicity was mild to moderate, also in terms of myelosuppression. Degree and extent of neutropenia and thrombocytopenia (grades 3-4 in 25.5% and, respectively, 22.5% of cycles) were lower than that observed with TPT, for which grades 3-4 neutropenia and thrombocytopenia were reported in 75% and 29.5% of cycles. The lower incidence of myelosuppression, mainly due to the dose selected for phase II, reflects the safe criteria for definition of heavily pretreated patients followed in the phase I. It is also notable that the few cases in whom a dose escalation was implemented, suffered from severe thrombocytopenia, which was DLT in phase I. The dose selected for the present study was therefore appropriate and not excessively toxic for patients, who often have a low PS and rapidly progressing disease.
The profile of non-hematological toxicity, consisting almost exclusively of grades 1-2 GI toxicity (vomiting in 11% of cycles, nausea in 22%), malaise and fatigue (34% of cycles) was comparable to that of TPT, for which vomiting, nausea and malaise were reported in 10.9%, 24.5% and 35.9% of the cycles, respectively.
We conclude that GI147211 is an active and well tolerated new agent in SCLC, comparable to TPT in terms of toxicity and antitumor activity but more expensive and that, as such, its further clinical development is not worthwhile.
The clinical evaluation of the oral formulation of GI147211, based on its high water solubility, has been discontinued due to drug company decision, while the interest in the compound has been recently renewed by the availability of the pegylated liposomal formulation SPI-355 with a five-fold higher therapeutic index [10] . In terms of antitumor activity SPI-355 appeared to be 20-fold more effective than GI147211 in inhibiting the tumor growth of the colon carcinoma xenografts HT-29, also inducing durable remissions. Additional pharmacokinetic data in mice and rats with the other liposomal formulation NX-211, administered on a single-or multiple-dosing schedule, indicated a 1000-fold greater AUC and a five-fold longer half-life for NX-211 than for GI147211 [11] ; the volume of distribution was decreased, thereby suggesting an extensive tissue distribution, with prolonged and increased concentrations in tumors.
These results of prolonged exposure, which may allow a less frequent dosing and improved therapeutic index, and the data of clinical activity of GI147211, provide a good new rationale for further evaluating lurtotecan (GI147211) once it is encapsulated in liposomes.
